CapsoVision (CV) Registration Filing summary

Company overview and business model

• Commercial-stage medical technology company focused on GI tract diagnostics using advanced imaging and AI in capsule endoscopy solutions.

• Core products include CapsoCam Plus (small bowel) and CapsoCam Colon (colon), both offering 360° panoramic imaging and cloud-based data management.

• CapsoCam Plus is FDA-cleared for small bowel use; CapsoCam Colon is in pivotal studies with FDA submission targeted for 2026.

• Revenue is generated primarily from direct sales to providers in the US and through distributors internationally.

• Long-term vision is a single ingestible capsule for multi-cancer screening using AI.

Financial performance and metrics

• 2024 revenue: $11.8 million, up 21% from $9.8 million in 2023; Q1 2025 revenue: $2.8 million, up 12% year-over-year.

• Net losses: $19.9 million in 2024, $11.3 million in 2023, and $5.4 million for Q1 2025; accumulated deficit of $135.7 million as of March 31, 2025.

• Gross margin: 54% in 2024, down from 56% in 2023.

• Cash as of March 31, 2025: $4.4 million; pro forma as adjusted post-IPO: $27.2 million.

• Substantial doubt about ability to continue as a going concern; additional capital likely needed beyond IPO proceeds.

Use of proceeds and capital allocation

• Estimated net proceeds of $22.8 million (at $5.25/share midpoint), with $8 million for R&D (AI, CapsoCam Colon, clinical studies), $1 million to repay a bridge loan, and the remainder for general corporate purposes.

• Proceeds expected to fund operations for at least 12 months; further capital raises may be required.